Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Posch

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 26, 2026
SH2D1A/SAP Reflects Immune Activation in Melanoma and Is a Superior Predictive Biomarker of Immune Checkpoint Inhibitor Response: A Proteomic AnalysisFederico Fusco, Johannes Weigel, Marius Schliemann, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREGValerie Glutsch, Patrick Schummer, Hermann Kneitz, et al.
Cancer Research|April 16, 2020
Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in MelanomaAnkit Patel, Lucia Fraile Garcia, Viviana Mannella, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and GermanyJulia Maria Ressler, Matthias Karasek, Lukas Koch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivoChristian Posch, Homayoun Moslehi, Luzviminda Feeney, et al.
JAMA Dermatology|September 5, 2014
The risk of melanoma in airline pilots and cabin crew: a meta-analysisMartina Sanlorenzo, Mackenzie R Wehner, Eleni Linos, et al.
Journal of the American Academy of Dermatology|February 10, 2025
Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidityAntonia Wiala, Kareem G Elhage, Andrea Leung, et al.
Research Square|September 24, 2024
Cellular indexing of transcriptomes and epitopes (CITE-Seq) in hidradenitis suppurativa identifies dysregulated cell types in peripheral blood and facilitates diagnosis via machine learningSugandh Kumar, Faye Orcales, Bobby B Shih, et al.
Biomedical Microdevices|February 6, 2015
Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticlesChristian Posch, Alfonso Latorre, Michelle B Crosby, et al.
The Journal of Investigative Dermatology|June 3, 2016
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant CellsChristian Posch, Martina Sanlorenzo, Igor Vujic, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 26, 2026
SH2D1A/SAP Reflects Immune Activation in Melanoma and Is a Superior Predictive Biomarker of Immune Checkpoint Inhibitor Response: A Proteomic AnalysisFederico Fusco, Johannes Weigel, Marius Schliemann, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREGValerie Glutsch, Patrick Schummer, Hermann Kneitz, et al.
Cancer Research|April 16, 2020
Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in MelanomaAnkit Patel, Lucia Fraile Garcia, Viviana Mannella, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and GermanyJulia Maria Ressler, Matthias Karasek, Lukas Koch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivoChristian Posch, Homayoun Moslehi, Luzviminda Feeney, et al.
JAMA Dermatology|September 5, 2014
The risk of melanoma in airline pilots and cabin crew: a meta-analysisMartina Sanlorenzo, Mackenzie R Wehner, Eleni Linos, et al.
Journal of the American Academy of Dermatology|February 10, 2025
Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidityAntonia Wiala, Kareem G Elhage, Andrea Leung, et al.
Research Square|September 24, 2024
Cellular indexing of transcriptomes and epitopes (CITE-Seq) in hidradenitis suppurativa identifies dysregulated cell types in peripheral blood and facilitates diagnosis via machine learningSugandh Kumar, Faye Orcales, Bobby B Shih, et al.
Biomedical Microdevices|February 6, 2015
Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticlesChristian Posch, Alfonso Latorre, Michelle B Crosby, et al.
The Journal of Investigative Dermatology|June 3, 2016
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant CellsChristian Posch, Martina Sanlorenzo, Igor Vujic, et al.
Pageof 10